Septerna, Inc. (SEPN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Septerna, Inc. (SEPN) trades at $40.79 with AI Score 32/100 (Grade D). Septerna, Inc. is a clinical-stage biotechnology company focused on developing oral small molecule drugs targeting G protein-coupled receptors (GPCRs). Market cap: $1.84B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 4, 2026SEPN stock analysis for 2026: Analysts have set a consensus price target of $35.67 for Septerna, Inc., suggesting 12.6% downside from the current price of $40.79. The AI MoonshotScore is 32/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
SEPN: 2/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Septerna, Inc. (SEPN) Healthcare & Pipeline Overview
Septerna, Inc. is a clinical-stage biotechnology firm specializing in oral small molecule GPCR-targeted therapeutics for endocrinology, immunology, inflammation, and metabolic disorders. Their innovative approach aims to address unmet needs in treating diseases like hypoparathyroidism, chronic urticaria, Graves' disease, obesity, and type 2 diabetes, setting them apart in the competitive biotech landscape.
What Is the Investment Thesis for SEPN?
Septerna, Inc. presents a notable research candidate due to its focus on GPCR-targeted oral small molecule therapeutics, addressing significant unmet needs in endocrinology, immunology, inflammation, and metabolic diseases. The company's lead candidate, SEP-786, targeting hypoparathyroidism, and SEP-631, for chronic urticaria, represent near-term value drivers. With a market capitalization of $1.84B and a 100% gross margin, Septerna demonstrates financial strength. Upcoming clinical trial results for SEP-786 and SEP-631 serve as key catalysts. The ongoing development of oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, including obesity and type 2 diabetes, offers long-term growth potential. However, the company's negative profit margin of -106.4% and high beta of 3.50 indicate substantial risk. Successful clinical trials and eventual commercialization are critical for Septerna to realize its potential.
Based on FMP financials and quantitative analysis
SEPN Key Highlights
Market capitalization of $1.84B reflects investor confidence in Septerna's pipeline and technology.
- Gross margin of 100.0% indicates strong potential profitability upon successful commercialization of drug candidates.
- Negative profit margin of -106.4% highlights the current stage of the company as a clinical-stage biotech with significant R&D expenses.
- Beta of 3.50 suggests high volatility relative to the market, typical for biotech companies with binary clinical trial outcomes.
- Focus on oral small molecule GPCR-targeted therapeutics differentiates Septerna from competitors primarily developing injectable biologics.
Who Are SEPN's Competitors?
SEPN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| TNGX Tango Therapeutics, Inc. | $23.51 | -6.71% | $3.83B | — |
| GLPG Galapagos NV | $27.98 | +1.71% | $1.84B | 70 |
| ETON Eton Pharmaceuticals, Inc. | $59.91 | -2.55% | $1.64B | 98 |
| VCEL Vericel Corporation | $42.11 | -3.35% | $2.16B | 94 |
| INVA Innoviva, Inc. | $21.04 | -2.05% | $1.55B | 94 |
| HRMY Harmony Biosciences Holdings, Inc. | $38.32 | -4.04% | $2.22B | 98 |
| ADMA ADMA Biologics, Inc. | $9.81 | -2.34% | $2.27B | 91 |
| MGTX MeiraGTx Holdings plc | $14.86 | -0.74% | $1.38B | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SEPN's Key Strengths?
Focus on oral small molecule drugs targeting GPCRs.
- Diverse pipeline addressing multiple therapeutic areas.
- Experienced management team with expertise in drug development.
- Strong intellectual property portfolio.
What Are SEPN's Weaknesses?
Clinical-stage company with no currently marketed products.
- High R&D expenses and negative profit margin.
- Reliance on successful clinical trial outcomes.
- Competition from larger pharmaceutical companies.
What Could Drive SEPN Stock Higher?
SEPN catalyst: Clinical trial results for SEP-786 in hypoparathyroidism are expected in Q4 2026, which could validate the efficacy of the PTH1R agonist.
- Data readout from the Phase 2 trial of SEP-631 for chronic spontaneous urticaria is anticipated in Q1 2027, potentially demonstrating the drug's effectiveness in treating mast cell diseases.
- Advancement of the TSHR program into Phase 1 clinical trials for Graves' disease and thyroid eye disease by mid-2027, marking a significant step in the development of this novel therapy.
- Continued development of oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, with potential for future clinical trials.
- Potential for strategic partnerships with larger pharmaceutical companies to accelerate the commercialization of Septerna's drug candidates.
What Are the Key Risks for SEPN?
Negative return on equity (-6.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays could significantly impact the company's valuation and future prospects.
- Regulatory hurdles and approval delays could delay the commercialization of Septerna's drug candidates.
- Competition from existing and emerging therapies in the endocrinology, immunology, and metabolic disease markets.
- High R&D expenses and negative profit margin require careful financial management and potential need for additional funding.
- Patent challenges or infringement could threaten the company's intellectual property and competitive advantage.
What Are the Growth Opportunities for SEPN?
- SEP-786 for Hypoparathyroidism: Septerna's SEP-786 targets hypoparathyroidism, a market with limited treatment options. The global hypoparathyroidism market is projected to reach $1.8 billion by 2028. Successful clinical trials and subsequent FDA approval could position SEP-786 as a leading oral treatment, capturing a significant market share. The timeline for potential commercialization is estimated within the next 3-5 years, contingent on positive clinical data.
- SEP-631 for Chronic Spontaneous Urticaria: SEP-631 addresses chronic spontaneous urticaria (CSU), a condition affecting millions worldwide. The CSU market is expected to grow to $5.2 billion by 2027. As an oral MRGPRX2 NAM, SEP-631 offers a novel approach compared to existing treatments. Positive clinical trial results could lead to rapid adoption and market penetration. Commercialization is anticipated within 3-5 years, pending regulatory approvals.
- TSHR Program for Graves' Disease and Thyroid Eye Disease: Septerna's TSHR program targets Graves' disease and thyroid eye disease, autoimmune disorders with significant unmet needs. The market for thyroid eye disease is projected to reach $3.2 billion by 2028. An oral TSHR NAM could provide a convenient and effective alternative to current therapies. Clinical development and potential commercialization are expected within 5-7 years.
- Incretin Receptor Agonists for Metabolic Disorders: Septerna is developing oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, including obesity and type 2 diabetes. The global market for diabetes and obesity treatments is substantial, projected to reach $56.5 billion by 2028. These agonists offer a potential alternative to injectable GLP-1 receptor agonists. Clinical trials and commercialization are anticipated within 5-7 years.
- Expansion of GPCR-Targeted Pipeline: Septerna's expertise in GPCR-targeted drug discovery provides opportunities to expand its pipeline into additional therapeutic areas. By leveraging its platform and knowledge, Septerna can identify and develop novel oral small molecule drugs for other diseases with unmet needs. This expansion could drive long-term growth and diversify the company's revenue streams. The timeline for new programs varies, but initial clinical candidates could emerge within 3-5 years.
What Are SEPN's Competitive Advantages?
- Proprietary GPCR-targeted drug discovery platform.
- Patent protection for novel drug candidates.
- Oral small molecule formulation offering convenience over injectable biologics.
- Expertise in developing drugs for specific GPCR targets.
What Does SEPN Do?
Septerna, Inc., established in 2019 and based in South San Francisco, California, is a clinical-stage biotechnology company dedicated to discovering and developing novel oral small molecule therapeutics. These therapeutics target G protein-coupled receptors (GPCRs), a class of proteins crucial in cell signaling and implicated in various diseases. Originally named GPCR NewCo, Inc., the company rebranded as Septerna Inc. in June 2021, marking a strategic shift towards its current focus. Septerna's approach involves creating oral medications that can selectively modulate GPCR activity, offering potential advantages over traditional injectable biologics. The company's pipeline includes several promising drug candidates. SEP-786 is an oral small molecule PTH1R agonist being developed for the treatment of hypoparathyroidism. SEP-631 is an oral small molecule MRGPRX2 NAM intended for chronic spontaneous urticaria and other mast cell diseases. The TSHR Program focuses on developing an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. Additionally, Septerna is developing oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, including obesity and type 2 diabetes. These programs reflect Septerna's commitment to addressing significant unmet medical needs with innovative oral therapies. Septerna's focus on GPCRs is significant because these receptors are involved in a wide range of physiological processes, making them attractive targets for drug development. By creating oral small molecule drugs that can selectively modulate GPCR activity, Septerna aims to provide patients with convenient and effective treatments for various diseases.
What Products and Services Does SEPN Offer?
- Discovers and develops oral small molecule drugs.
- Targets G protein-coupled receptors (GPCRs).
- Develops therapies for endocrinology disorders.
- Creates treatments for immunology and inflammation.
- Addresses metabolic diseases like obesity and type 2 diabetes.
- Focuses on oral alternatives to injectable biologics.
- Conducts clinical trials to evaluate drug efficacy and safety.
How Does SEPN Make Money?
- Develops and patents novel oral small molecule drugs.
- Conducts preclinical and clinical trials to demonstrate efficacy and safety.
- Seeks regulatory approval from agencies like the FDA.
- Potentially partners with larger pharmaceutical companies for commercialization or out-licensing.
What Industry Does SEPN Operate In?
Septerna operates within the biotechnology industry, which is characterized by high growth potential and substantial risk. The market for GPCR-targeted therapeutics is significant, driven by the involvement of GPCRs in numerous diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms. Septerna's focus on oral small molecule drugs provides a competitive advantage over companies developing injectable biologics, offering convenience and potentially lower costs. The industry is subject to stringent regulatory requirements and lengthy clinical trial processes.
Who Are SEPN's Key Customers?
- Patients suffering from endocrinology disorders like hypoparathyroidism.
- Patients with immunological and inflammatory conditions such as chronic spontaneous urticaria.
- Individuals with metabolic diseases including obesity and type 2 diabetes.
- Healthcare providers prescribing treatments for these conditions.
Forward Outlook
Wall Street analysts project Septerna, Inc. revenue of about $77.0M for fiscal 2026, with EPS near $-1.65. The estimate reflects 8 contributing analysts.
Financial Health
Septerna, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 6.71 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for Septerna, Inc. stands at -6.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.3%, showing how much profit it generates from its asset base. Its free cash flow yield is 4.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.99 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.1%, the inverse of the P/E and a quick read on earnings relative to price.
Septerna, Inc. (SEPN) Valuation Context
Valued at $1.84B, SEPN is classified as a small-cap stock. Relative to its peer group, SEPN's quantitative score of 32/100 is below the peer average of 89/100.
Company Profile
Septerna, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Jeffrey T. Finer. SEPN has traded publicly since 2024.
SEPN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Septerna's focus on GPCR-targeted therapies is gaining traction; these receptors are implicated in many diseases.
- Recent insider buying suggests confidence in Septerna's pipeline and strategy.
- Community sentiment indicates growing optimism about Septerna's potential to disrupt the drug discovery process.
- Market perception is improving as Septerna advances its programs toward clinical trials.
Bear Case
- Septerna is still in early stages, with no products on the market, resulting in inherent development risks.
- Community discussions reveal concerns about the long timeline and high costs associated with drug development.
- Market perception reflects uncertainty around Septerna's ability to successfully navigate regulatory hurdles.
- Recent insider selling, if any, might signal a lack of confidence in the short-term prospects (data suggests but unconfirmed).
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SEPN Latest News
SEPN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SEPN.
Price Targets
Consensus target: $35.67
SEPN MoonshotScore
What does this score mean?
The MoonshotScore rates SEPN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jeffrey T. Finer
CEO
Jeffrey T. Finer serves as the CEO of Septerna, Inc., bringing extensive experience in the biotechnology industry. His career includes leadership roles in various pharmaceutical and biotech companies, focusing on drug development and commercialization. Finer's background encompasses strategic planning, clinical operations, and business development, making him well-suited to guide Septerna through its clinical development programs. His expertise is crucial for navigating the complexities of the biotechnology sector and driving the company's growth.
Track Record: Under Jeffrey T. Finer's leadership, Septerna has advanced its pipeline of GPCR-targeted oral small molecule drugs. He has overseen the progression of SEP-786 and SEP-631 into clinical trials and has guided the development of the TSHR program and incretin receptor agonists. His strategic decisions have focused on maximizing the value of Septerna's GPCR platform and securing partnerships to support the company's growth.
SEPN Healthcare Stock FAQ
What does the AI Score mean for SEPN?
SEPN holds an AI Score of 32/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Septerna, Inc. is a clinical-stage biotechnology company focused on developing oral small molecule drugs targeting G protein-coupled receptors (GPCRs). Their pipeline addresses endocrinology …
What does Septerna, Inc. do?
Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing oral small molecule drugs that target G protein-coupled receptors (GPCRs). These receptors play a crucial role in cell signaling and are implicated in various diseases. Septerna's pipeline includes drug candidates for endocrinology, immunology, inflammation, and metabolic diseases, including hypoparathyroidism, chronic spontaneous urticaria, Graves' disease, and obesity.
What do analysts say about SEPN stock?
Analyst coverage of Septerna, Inc. is still emerging given its recent public listing. Current sentiment reflects cautious optimism, acknowledging the potential of its GPCR-targeted drug pipeline. Key valuation metrics are focused on the long-term potential of its clinical programs, with successful clinical trial outcomes being critical for driving stock appreciation. Investors should closely monitor clinical trial results and regulatory milestones to assess the company's progress and potential risks.
What are the main risks for SEPN?
The primary risks for Septerna, Inc. include the inherent uncertainties of clinical drug development, particularly the potential for clinical trial failures or delays. Regulatory hurdles and approval delays also pose significant risks. Competition from established pharmaceutical companies and emerging therapies in the endocrinology, immunology, and metabolic disease markets could limit Septerna's market share.
What are the key factors to evaluate for SEPN?
Septerna, Inc. (SEPN) holds an AI score of 32/100 (low). Analysts target $35.67 (-13%). presents a notable research candidate due to its focus on GPCR-targeted oral small molecule therapeutics, addressing significant unmet needs in endocrinology, immunology, inflammation, and metabolic diseases. Not financial advice.
How frequently does SEPN data refresh on this page?
SEPN's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SEPN's recent stock price performance?
Septerna, Inc. (SEPN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on oral small molecule drugs targeting GPCRs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SEPN overvalued or undervalued right now?
Septerna, Inc. (SEPN) is loss-making, so its trailing P/E is negative (-13.6x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Analysts target $35.67 (-13%) — downside risk seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SEPN before investing?
Before investing in Septerna, Inc. (SEPN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Clinical trial outcomes are inherently uncertain and can significantly impact company prospects.